190 related articles for article (PubMed ID: 34008499)
21. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
22. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
24. Endometrial Cancer Risk Among Germline
Sorouri K; Lynce F; Feltmate CM; Davis MR; Muto MG; Konstantinopoulos PA; Stover EH; Kurian AW; Hill SJ; Partridge AH; Tolaney SM; Garber JE; Bychkovsky BL
JCO Precis Oncol; 2023 Sep; 7():e2300290. PubMed ID: 38061009
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
26. Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
McCrorie AD; Ashfield S; Begley A; Mcilmunn C; Morrison PJ; Boyd C; Eccles B; Greville-Heygate S; Copson ER; Cutress RI; Eccles DM; Savage KI; McIntosh SA
J Pathol Clin Res; 2020 Apr; 6(2):146-153. PubMed ID: 32022473
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Stevens KN; Wang X; Fredericksen Z; Pankratz VS; Greene MH; Andrulis IL; Thomassen M; Caligo M; ; Nathanson KL; Jakubowska A; Osorio A; Hamann U; Godwin AK; Stoppa-Lyonnet D; Southey M; Buys SS; Singer CF; Hansen TV; Arason A; Offit K; Piedmonte M; Montagna M; Imyanitov E; Tihomirova L; Sucheston L; Beattie M; ; ; Neuhausen SL; ; Szabo CI; ; Simard J; Spurdle AB; Healey S; Chen X; Rebbeck TR; Easton DF; Chenevix-Trench G; Antoniou AC; Couch FJ
Breast Cancer Res Treat; 2012 Nov; 136(1):295-302. PubMed ID: 23011509
[TBL] [Abstract][Full Text] [Related]
28. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Ricks-Santi L; McDonald JT; Gold B; Dean M; Thompson N; Abbas M; Wilson B; Kanaan Y; Naab TJ; Dunston G
Ethn Dis; 2017; 27(2):169-178. PubMed ID: 28439188
[TBL] [Abstract][Full Text] [Related]
29. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
30. Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.
Choi MC; Heo JH; Jang JH; Jung SG; Park H; Joo WD; Lee C; Lee JH; Lee JM; Hwang YY; Kim SJ
Int J Gynecol Cancer; 2015 Oct; 25(8):1386-91. PubMed ID: 26402875
[TBL] [Abstract][Full Text] [Related]
31. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
32. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
[TBL] [Abstract][Full Text] [Related]
33. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Spurdle AB; Marquart L; McGuffog L; Healey S; Sinilnikova O; Wan F; Chen X; Beesley J; Singer CF; Dressler AC; Gschwantler-Kaulich D; Blum JL; Tung N; Weitzel J; Lynch H; Garber J; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Conroy D; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Selkirk CG; Daly M; Isaacs C; Stoppa-Lyonnet D; Sinilnikova OM; Buecher B; Belotti M; Mazoyer S; Barjhoux L; Verny-Pierre C; Lasset C; Dreyfus H; Pujol P; Collonge-Rame MA; ; Rookus MA; Verhoef S; Kriege M; Hoogerbrugge N; Ausems MG; van Os TA; Wijnen J; Devilee P; Meijers-Heijboer HE; Blok MJ; Heikkinen T; Nevanlinna H; Jakubowska A; Lubinski J; Huzarski T; Byrski T; Durocher F; Couch FJ; Lindor NM; Wang X; Thomassen M; Domchek S; Nathanson K; Caligo M; Jernström H; Liljegren A; Ehrencrona H; Karlsson P; ; Ganz PA; Olopade OI; Tomlinson G; Neuhausen S; Antoniou AC; Chenevix-Trench G; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
[TBL] [Abstract][Full Text] [Related]
34. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
35. Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Smolarz B; Romanowicz H
Int J Clin Exp Pathol; 2018; 11(3):1732-1738. PubMed ID: 31938277
[No Abstract] [Full Text] [Related]
36. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
Reitsma W; de Bock GH; Oosterwijk JC; ten Hoor KA; Hollema H; Mourits MJ
Int J Gynecol Cancer; 2012 May; 22(4):579-85. PubMed ID: 22274543
[TBL] [Abstract][Full Text] [Related]
37. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
[TBL] [Abstract][Full Text] [Related]
39. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
40. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]